1	Diagnostic Performance and Characteristics of Anterior Nasal Collection for the SARS-
2	CoV-2 Antigen Test: A Prospective Study in Japan
3	
4	Yuto Takeuchi, a,b Yusaku Akashi, b,c# Daisuke Kato,d Miwa Kuwahara,d Shino Muramatsu,d
5	Atsuo Ueda, <sup>e</sup> Shigeyuki Notake, <sup>e</sup> Koji Nakamura, <sup>e</sup> Hiroichi Ishikawa, <sup>f</sup> Hiromichi Suzuki, <sup>a,b,g</sup>
6	
7	<sup>a</sup> Department of Infectious Diseases, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
8	<sup>b</sup> Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital,
9	Tsukuba, Ibaraki, Japan
10	<sup>c</sup> Akashi Internal Medicine Clinic, Kashiwara, Osaka, Japan
11	<sup>d</sup> Denka Co., Ltd. Gosen site, Reaserch & Development Division, Reagent R&D Depertment,
12	Gosen, Niigata, Japan
13	<sup>e</sup> Department of Clinical Laboratory, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki,
14	Japan
15	<sup>f</sup> Department of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki,

Japan

17	Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba, Tsukuba,
18	Ibaraki, Japan
19	
20	Running Head: SARS-CoV-2 antigen test with anterior nasal sample
21	
22	#Address correspondence to Yusaku Akashi, yusaku-akashi@umin.ac.jp
23	Author order was determined in order of increasing seniority.
24	

### ABSTRACT

We conducted a prospective study in Japan to evaluate the diagnostic performance of the antigen test QuickNavi-COVID19 Ag using anterior nasal samples and to compare the degrees of coughs or sneezes induction and the severity of pain between anterior nasal collection and nasopharyngeal collection. A total of 862 participants were included in the analysis. In comparison to the findings of reverse transcription PCR using nasopharyngeal samples, the antigen test using anterior nasal samples showed 72.5% sensitivity (95% confidence interval [CI]: 58.3%-84.1%) and 100% specificity (95% CI: 99.3%-100%). Anterior nasal collection was associated with a significantly lower degree of coughs or sneezes induction and the severity of pain in comparison to nasopharyngeal collection (p < 0.001). The antigen test using anterior nasal samples showed moderate sensitivity but was less painful and induced fewer coughs or sneezes.

### INTRODUCTION

38

39 The laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) includes nucleic acid amplification tests (NAATs), antigen tests, and antibody tests (1). 40 Antigen tests are generally less sensitive than NAATs for detecting SARS-CoV-2 but are 41 relatively inexpensive, and most can be performed at the point of care (2). 42 43 The diagnostic performance of antigen test of nasopharyngeal samples has been evaluated, and the reported specificity is consistently high > 97%, while sensitivity ranges from 0% to 44 45 94% (2). We previously evaluated the performance of an antigen test, QuickNavi-COVID19 Ag (Denka Co., Ltd., Tokyo, Japan), using nasopharyngeal samples from 1186 participants 46 47 (3). The overall sensitivity and specificity were 86.7% (95% confident interval [CI]: 78.6% -92.5%) and 100% (95% CI: 99.7%-100%), respectively, and the sensitivity for symptomatic 48 participants was 91.7% (95% CI: 82.7%-96.9%) (3). 49 In recent studies, the sensitivity of anterior nasal samples was reported to be comparable 50 to that of nasopharyngeal samples for NAATs (4, 5). Anterior nasal collection was reported 51 to be less painful than nasopharyngeal collection (6) and may cause less droplet dispersal. 52 These benefits are also expected in antigen tests but have yet to be fully evaluated. 53

- We prospectively evaluated the diagnostic performance of the QuickNavi-COVID19 Ag
- test using anterior nasal samples and compared the degrees of coughs or sneezes induction
- and the severity of pain between anterior nasal collection and nasopharyngeal collection.

MATERIALS AND METHODS

58

59

60

61

62

63

64

65

66

67

68

70

71

72

73

74

We conducted the present prospective study between October 7, 2020 and January 9, 2021, at a drive-through PCR center where participants were referred from a local public health center and 97 primary care facilities in Tsukuba, Japan. After receiving the participants' informed consent, additional anterior nasal samples for the antigen test were collected and their clinical information was obtained. Cases with no clinical data were excluded from this study. In cases where participants enrolled in the current study more than once, only the first evaluation was included in this study. The present study was approved by the ethics committee of Tsukuba Medical Center Hospital (approval number: 2020-033).

# Sample collection and the antigen test procedure

We simultaneously obtained an anterior nasal sample for the antigen test and a

nasopharyngeal sample for the PCR examination. All samples were obtained with

FLOQSwabs (Copan Italia S.p.A., Brescia, Italy).

The anterior nasal sample was initially collected according to the manufacturer's

instructions. Namely, a nasopharyngeal-type flocked (NP-type) swab was inserted to 2 cm

depth in one nasal cavity, rotated five times, and held in place for five seconds. The antigen

test using the QuickNavi-COVID19 Ag kit was performed immediately after anterior nasal

collection and the result was obtained by the visual interpretation of each examiner.

A nasopharyngeal sample was subsequently collected with an NP-type swab according to

a previously described procedure (7) and was diluted in 3 mL of Universal Transport Medium

(UTM) (Copan Italia S.p.A., Brescia, Italy). The UTM was transferred to an in-house

microbiology laboratory located next to the drive-through sample-collecting site of the PCR

center within an hour of sample collection.

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

## SARS-CoV-2 detection using reverse transcription PCR

After the arrival of the UTM samples, purification and RNA extraction were performed

with magLEAD 6gC (Precision System Science Co., Ltd., Chiba, Japan) from 200 µL

aliquots of UTM for in-house reverse transcription (RT)-PCR on the same day as sample

collection. RNA was eluted in 100 µL and stored at -80 °C after the in-house RT-PCR test.

The eluted samples were transferred to Denka Co., Ltd., every week for a reference real-time

RT-PCR test on Applied Biosystems QuantStudio 3 (Thermo Fisher Scientific Inc., Waltham,

MA, USA) using a QuantiTect Probe RT-PCR Kit (QIAGEN Inc., Germantown, MD, USA)

and primer/probe N and N2 set (8).

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

The presence or absence of SARS-CoV-2 was defined by the results of the reference realtime RT-PCR test. However, if discordance existed between the reference real-time RT-PCR test and the in-house RT-PCR test, a re-evaluation was performed with an Xpert Xpress SARS-CoV-2 and GeneXpert System (Cepheid, Sunnyvale, CA, USA), the results of which provided the final judgment. The degrees of coughs or sneezes and the severity of pain induced by the sample collection procedure The degrees of coughs or sneezes and the severity of pain caused by the insertion of the swab into the anterior nasal cavity and nasopharynx in the same participant were assessed. Examiners rated the degrees of coughs or sneezes induction from the following four categories: "None", "Small, 1-2 times", "Loud, 1-2 times" and "Loud, multiple times". The severity of pain was evaluated with a five-point scale (Pain score), with 1 being "no pain" and 5 being "worst imaginable pain," and the participants were asked to report a number from the scale.

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

The comparison of SARS-CoV-2 viral loads between different sample collection sites and swab types We conducted an additional experiment to evaluate whether the viral loads differed between sample collection sites and swab types between January 8 and 19, 2021. After receiving the participants' informed consent, two anterior nasal samples were obtained from the participants for whom a nasopharyngeal sample had already tested positive for SARS-CoV-2. Two anterior nasal swab samples were collected from each nostril using one with a NP-type swab and the other with an oropharyngeal-type flocked (OP-type) swab. These sample collections were performed on the same day. The samples were diluted in 3 mL of UTM, and stored at -80°C. After several days of storage, the samples were thawed, and purification and RNA extraction were performed according to the above-described method. The viral concentrations in samples were quantified with the following procedure. The calibration curves were generated with 5, 50, and 500 copies/reaction of positive control (EDX SARS-CoV-2 Standard; Bio-Rad Laboratories, Inc., Hercules, CA, USA). Quantitative RT-PCR was performed on a LightCycler 96 System (Roche, Basel, Switzerland) using a THUNDERBIRD Probe One-

step qRT-PCR Kit (TOYOBO Co. Ltd., Osaka, Japan) with a primer/probe N2 set.

Statistical analyses

The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of QuickNavi-COVID19 Ag and their 95% confidence intervals (CIs) were calculated with the Clopper and Pearson method. The viral loads according to collection sites and swab types were compared by the Wilcoxon signed-rank test with Holm correction. The degrees of coughs or sneezes induction and the pain score were also compared between the two different collection procedures using the McNemar-Bowker test and the Wilcoxon signed-rank test, respectively. P values of < 0.05 were considered to indicate statistical significance. All statistical analyses were conducted using the R 3.5.2 software program (The R Foundation, Vienna, Austria).

**RESULTS** 

## Viral loads in different sample collection sites and swab types

In 32 identical SARS-CoV-2 positive cases, we evaluated the SARS-CoV-2 viral loads of nasopharyngeal samples (NPS), anterior nasal samples with NP-type swabs (AWN), and anterior nasal samples with OP-type swabs (AWO) (Fig. 1). The median viral loads for NPS, AWN, and AWO were 53,560 (interquartile range [IQR]: 605-608,050), 1,792 (IQR: 7-81,513), and 6,369 (IQR: 7-97,535), respectively. With the NPS as a reference, the PCR-positive rate for AWN was 84.4% (27/32;95% CI: 67.2%-94.7%), while that for AWO was 81.3% (26/32; 95% CI: 63.6%-92.8%). In comparison to NPS, the viral load was significantly lower with AWN (p < 0.001) and AWO (p < 0.001), but there was no significant difference between AWN and AWO (p = 0.61). The viral loads and Ct values for all samples are described in Table S1a and Table S1b.

## **Demographic data of study population**

A total of 876 participants were screened for the evaluation. Most samples were obtained at the drive-through PCR center, and only 17 were obtained after hospitalization. We

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

excluded the participants who underwent duplicate tests (n=7) or for whose clinical information were lacking (n=7). Finally, 862 participants were included in the analysis. Among the 862 participants, SARS-CoV-2 was detected in 50 (5.8%) on nasopharyngeal samples by the reference real-time RT-PCR test. There was one discordant sample that was positive on the in-house RT-PCR test and negative on the reference real-time RT-PCR test. The Xpert Xpress SARS-CoV-2 test provided a positive result for the sample (cycle threshold [Ct] values for E and N2 targets: 0.0 and 39.8, respectively); thus, 51 (5.9%) participants were finally considered positive for SARS-CoV-2. The discordant sample was obtained from a participant who had been diagnosed with COVID-19 one month before the current evaluation and who was referred to the PCR center due to refractory respiratory symptoms. All 51 participants who were positive for SARS-CoV-2 were symptomatic (Table 1a); their characteristics are described in Table 1b. The most common symptom was fever (80.4%), followed by cough or sputum production (60.8%), sore throat (37.3%), runny nose or nasal congestion (35.5%), and loss of taste or smell (27.5%).

## Diagnostic performance of QuickNavi-COVID19 Ag using anterior nasal samples

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

Of the 51 participants who were found to be SARS-CoV-2-positive by the RT-PCR test, 37 participants were found to be positive with the antigen test with anterior nasal samples (Table 2). Among the 811 SARS-CoV-2-negative participants, all participants were found to be negative with the antigen test (Table 2). The concordance rate between the antigen test and RT-PCR was thus 98.4% (95% CI: 97.3%-99.1%). The sensitivity, specificity, PPV, and NPV were 72.5% (95% CI: 58.3%-84.1%), 100% (95% CI: 99.3%-100%), 100% (95% CI: 86.2%-100%), and 98.3% (95%CI: 97.2%-99.1%), respectively (Table 2). Comparison of degrees of coughs or sneezes induction and the severity of pain between anterior nasal and nasopharyngeal sample collection The degrees of coughs or sneezes induced by sample collection was measured in 784 participants (Fig. 2). Coughing or sneezing was observed in 149 (19.0%) of anterior nasal collections and in 316 (40.3%) of nasopharyngeal collection. When coughs or sneezes occurred in anterior nasal collection, their degrees were significantly lower than in nasopharyngeal collection (p < 0.001). The pain score was obtained from 90 participants (Fig. 3). Fifty-seven participants (63.3%) reported no pain in anterior nasal collection. The median pain score of anterior nasal

collection and nasopharyngeal collection was 1 (IQR: 1-2) and 3 (IQR: 2-4), respectively. In

comparison to nasopharyngeal collection, anterior nasal collection was significantly less

188 painful (p < 0.001).

186

### **DISCUSSION**

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

The QuickNavi-COVID19 Ag test using anterior nasal samples showed 72.5% sensitivity and 100% specificity. In comparison to nasopharyngeal collection, anterior nasal collection was less painful and was associated with fewer coughs or sneezes. In addition, the study demonstrated that the viral load of anterior nasal samples was significantly lower than that of nasopharyngeal samples. Meanwhile, the swab types did not influence the viral load of anterior nasal samples. In the current study, anterior nasal samples provided a lower antigen test sensitivity than our previous study evaluating nasopharyngeal samples (3). The sensitivity of antigen tests is largely influenced by the viral load in collected samples (9–12). The QuickNavi-COVID19 Ag test could detect SARS-CoV-2 in almost all samples with Ct values < 30, and in 18.8% of samples with Ct values > 30 (3). The viral load may vary between collection sites (13), and this study recognized the viral load of samples was significantly lower when they were collected from the anterior nasal cavity (Fig. 1). This lower viral load in anterior nasal samples could explain the decreased sensitivity. On the other hand, the QuickNavi-COVID19 Ag test provided 100% specificity in both the present study and our previous study (3). Although it is necessary to verify whether similar results can be obtained in other settings,

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

false positives should be avoided to prevent unnecessary additional testing and inappropriate isolation measures (14). We observed that anterior nasal collection caused fewer coughs or sneezes in comparison to nasopharyngeal sample collection (Fig. 2). Notably, anterior nasal collection induced coughs or sneezes in only 19% of participants. Coughs or sneezes generate droplets and prolong their dispersal by forming multiphase turbulent gas clouds (15), which leads to greater droplet exposure. SARS-CoV-2 is mainly transmitted through droplets (16); thus, anterior nasal collection, which was associated with fewer coughs or sneezes induction, may reduce the transmission risk among healthcare providers. Anterior nasal collection was less painful (Fig. 3), with more than half of the participants reporting no pain from the procedure. Nasopharyngeal collection is an uncomfortable and painful experience (6) and may discourage patients from receiving tests. Besides, nasopharyngeal collection may not be applicable if patients have a history of recent nasal trauma or surgery, remarkable nasal septum deviation, or marked coagulopathy (7). Despite the decreased sensitivity, when NAATs are not readily available, an antigen test with anterior nasal samples may be an option in these clinical contexts.

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

The selection of swab type influences the uptake, extraction and recovery efficiency of the collected sample (17, 18). In this study, we compared two flocked swabs with different tip sizes (NP-type and OP-type swab). There was no significant difference in the viral load of the samples collected with the two types of swabs; however, the OP-type swab has a larger tip and seemed to handle a larger amount of samples collected. A previous study suggested that the efficiency of sample release was not associated with the absorbed volume (19), which could explain the result in this study. The present study was associated with some limitations. First, the samples used for the reference real-time RT-PCR test were frozen and transported. Although the samples were frozen at -80°C, the viral loads may have been decreased during the storage and transport process. Nevertheless, in the case of discrepancy with in-house PCR, re-evaluation was performed and did not affect the calculation of the sensitivity of the antigen test. Second, asymptomatic SARS-CoV-2 positive patients were unintentionally not included in this study. Further study is required to evaluate the clinical performance of the antigen test in those patients. Finally, this study was conducted at a single center, although participants were referred from multiple primary facilities. Further research should be conducted to assess the generalizability of the findings.

In conclusion, the QuickNavi-COVID19 Ag test with an anterior nasal sample showed 100% specificity; however, the sensitivity in the detection of SARS-CoV-2 was lower in comparison to the QuickNavi-COVID19 Ag test with nasopharyngeal samples. Anterior nasal collection was less invasive and induced fewer coughs or sneezes, which may be more comfortable for the patient and may reduce the risk of droplet exposure to healthcare workers.

246

247

248

249

250

251

252

253

254

255

256

257

258

259

**ACKNOWLEDGEMENTS** We thank Mrs. Yoko Ueda, Mrs. Mio Matsumoto, Dr. Yumi Hirose and the staff in the Department of Clinical Laboratory of Tsukuba Medical Center Hospital for their intensive support of this study. We thank all of the medical institutions for providing their patients' clinical information. Mrs. Yoko Ueda and Mrs. Mio Matsumoto significantly contributed to creating the database of this study. Denka Co., Ltd., provided fees for research expenses and the QuickNavi-COVID19 Ag kits without charge. Hiromichi Suzuki received a lecture fee from Otsuka Pharmaceutical Co., Ltd., regarding this study. Daisuke Kato, Miwa Kuwahara and Shino Muramatsu belong to Denka Co., Ltd., the developer of the QuickNavi-COVID19 Ag. **REFERENCES** World Health Organization. 2020. Diagnostic testing for SARS-CoV-2: interim 1. guidance, 11 September 2020. https://apps.who.int/iris/handle/10665/334254. Accessed 24 February 2021.

260	2.	World Health Organization. 2020. Antigen-detection in the diagnosis of SARS-CoV-
261		2 infection using rapid immunoassays: interim guidance, 11 September 2020.
262		https://apps.who.int/iris/handle/10665/334253. Accessed 24 February 2021.
263	3.	Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, Notake S,
264		Nakamura K, Ishikawa H, Suzuki H. 2021. The evaluation of a newly developed
265		antigen test (QuickNavi <sup>TM</sup> -COVID19 Ag) for SARS-CoV-2: A prospective
266		observational study in Japan. medRxiv
267		https://doi.org/10.1101/2020.12.27.20248876.
268	4.	Péré H, Podglajen I, Wack M, Flamarion E, Mirault T, Goudot G, Hauw-Berlemont
269		C, Le L, Caudron E, Carrabin S, Rodary J, Ribeyre T, Bélec L, Veyer D. 2020. Nasal
270		Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of
271		Nasopharyngeal Swab Shortage. J Clin Microbiol https://doi.org/10.1128/jcm.00721-
272		20.
273	5.	Tu Y-P, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, Verma P, Vojta
274		D, Berke EM. 2020. Swabs Collected by Patients or Health Care Workers for SARS-
275		CoV-2 Testing. N Engl J Med 383:494–496.

276	6.	Frazee BW, Rodríguez-Hoces de la Guardia A, Alter H, Chen CG, Fuentes EL,
277		Holzer AK, Lolas M, Mitra D, Vohra J, Dekker CL. 2018. Accuracy and Discomfort
278		of Different Types of Intranasal Specimen Collection Methods for Molecular
279		Influenza Testing in Emergency Department Patients. Ann Emerg Med 71:509-
280		517.e1.
281	7.	Marty FM, Chen K, Verrill KA. 2020. How to Obtain a Nasopharyngeal Swab
282		Specimen. N Engl J Med 382:e76.
283	8.	Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, Katoh H, Sakata M,
284		Nakatsu Y, Mori Y, Kageyama T, Matsuyama S, Takeda M. 2020. Development of
285		genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in
286		Japan. Jpn J Infect Dis 73:304–307.
287	9.	Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, Sueki
288		H, Hayakawa M, Mochizuki H, Tsutsui T, Kakizaki Y, Miyashita Y, Omata M.
289		2021. Prospective Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using
290		the LUMIPULSE SARS-CoV-2 Antigen Test: Comparison with RT-qPCR. Int J
291		Infect Dis https://doi.org/10.1016/j.ijid.2021.02.005.

292	10.	Aoki K, Nagasawa T, Ishii Y, Yagi S, Okuma S, Kashiwagi K, Maeda T, Miyazaki
293		T, Yoshizawa S, Tateda K. 2021. Clinical validation of quantitative SARS-CoV-2
294		antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs. J
295		Infect Chemother https://doi.org/10.1016/j.jiac.2020.11.021.
296	11.	Salvagno GL, Gianfilippi G, Bragantini D, Henry BM, Lippi G. 2021. Clinical
297		assessment of the Roche SARS-CoV-2 rapid antigen test. Diagnosis
298		https://doi.org/10.1515/dx-2020-0154.
299	12.	Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N,
300		Cilla G, Hernáez-Crespo S, Díaz-de Tuesta JL, Torrella AG, González-Romo F,
301		Escribano P, Sánchez-Castellano MÁ, Sota-Busselo M, Delgado-Iribarren A, García
302		J, Cantón R, Muñoz P, Folgueira MD, Cuenca-Estrella M, Oteo-Iglesias J, Medrano
303		S, Pérez A, Galar A, Martínez-Expósito O, Alejo-Cancho I, Martín-Higuera MC,
304		Rolo M, Estévez MJ, Bravo T, Vicente D, Montes M. 2021. Multicenter evaluation
305		of the Panbio <sup>TM</sup> COVID-19 rapid antigen-detection test for the diagnosis of SARS-
306		CoV-2 infection. Clin Microbiol Infect https://doi.org/10.1016/j.cmi.2021.02.001.
307	13.	Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021. Performance
308		of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular

Detection: A Systematic Review and Meta-analysis. J Clin Microbiol 309 310 https://doi.org/10.1128/jcm.02881-20. Ogawa T, Fukumori T, Nishihara Y, Sekine T, Okuda N, Nishimura T, Fujikura H, 14. 311 312 Hirai N, Imakita N, Kasahara K. 2020. Another false-positive problem for a SARS-CoV-2 antigen test in Japan. J Clin Virol 131:104612. 313 15. Bourouiba L. 2020. Turbulent Gas Clouds and Respiratory Pathogen Emissions: 314 315 Potential Implications for Reducing Transmission of COVID-19. JAMA - J Am Med 316 Assoc 323:1837-1838. World Health Organization. 2020. Transmission of SARS-CoV-2: implications for 16. 317 318 infection prevention precautions. https://www.who.int/publications/i/item/modes-oftransmission-of-virus-causing-covid-19-implications-for-ipc-precaution-319 recommendations. Accessed 24 February 2021. 320 Kahamba TR, Noble L, Stevens W, Scott L. 2020. Comparison of three 17. 321 nasopharyngeal swab types and the impact of physiochemical properties for optimal 322 SARS-CoV-2 detection. medRxiv https://doi.org/10.1101/2020.10.21.20206078. 323 Bruijns BB, Tiggelaar RM, Gardeniers H. 2018. The Extraction and Recovery 324 18. Efficiency of Pure DNA for Different Types of Swabs. J Forensic Sci 63:1492–1499. 325

Zasada AA, Zacharczuk K, Woźnica K, Główka M, Ziółkowski R, Malinowska E.
 2020. The influence of a swab type on the results of point-of-care tests. AMB
 Express https://doi.org/10.1186/s13568-020-00978-9.

Figure Legends 331 332 **FIG 1.** Comparison of SARS-CoV-2 viral loads between each collection site and swab type. The set of viral loads in the same participant is represented by connected lines. The viral 333 334 loads were compared by the Wilcoxon signed-rank test, and P values are corrected with Holm correction. NP swab, nasopharyngeal-type swab; OP swab, oropharyngeal-type swab; CI, 335 336 confidence interval; IQR, interquartile range. 337 338 **FIG 2.** Degrees of coughs or sneezes induced by anterior nasal and nasopharyngeal collection. The degrees of coughing or sneezing following swab insertion was compared between 339 340 anterior nasal collection and nasopharyngeal collection in the same participant (n = 784). The degrees were rated on a four-point scale. The McNemar-Bowker test was used for the 341 comparison. 342 343 FIG 3. The pain score in anterior nasal collection and nasopharyngeal collection. The 344 severity of pain at swab insertion was assessed on a five-point scale, from 1 to 5 (Pain score). 345 The pain score for each collection method was obtained from the same participant (n = 90). 346

- 347 The comparison of the pain scores with the two collection procedures was performed with
- the Wilcoxon signed-rank test.

Table 1a. Demographic data of the whole study population and cases infected with SARS-CoV-2

	T-4-1	SARS-CoV-2	
	Total -	Positive	Negative
N	862	51	811
Age (years, median [IQR])	36.0 [24.0, 48.0]	43.0 [30.0, 57.5]	35.0 [23.0, 47.0]
<18 years	106 (12.3)	2 (3.9)	104 (12.8)
18-64 years	678 (78.7)	44 (86.3)	634 (78.2)
≥ 65 years	78 (9.0)	5 (9.8)	73 (9.0)
Sex (Female)	383 (44.4)	19 (37.3)	364 (44.9)
Asymptomatic participants	72 (8.4)	0 (0.0)	72 (8.9)
Symptomatic participants	790 (91.6)	51 (100)	739 (91.1)

Table 1b. Characteristics of symptomatic participants and cases infected with SARS-CoV-2

	T-4-1	SARS	SARS-CoV-2	
	Total	Positive	Negative	
N	790	51	739	
Days from symptom onset	20110 201	2.0.12.0.5.01	20110201	
to sample collection [IQR]	2.0 [1.0, 3.0]	3.0 [2.0, 5.0]	2.0 [1.0, 3.0]	
Signs and symptoms				
Fever	628 (79.5)	41 (80.4)	587 (79.4)	
Cough/sputum production	255 (32.3)	31 (60.8)	224 (30.3)	
Runny nose/nasal congestion	185 (23.4)	18 (35.3)	167 (22.6)	
Loss of taste or smell	32 (4.1)	14 (27.5)	18 (2.4)	
Dyspnea	7 (0.9)	2 (3.9)	5 (0.7)	
Fatigue	105 (13.3)	10 (19.6)	95 (12.9)	
Diarrhea	48 (6.1)	1 (2.0)	47 (6.4)	
Sore throat	210 (26.6)	19 (37.3)	191 (25.8)	
Headache	121 (15.3)	11 (21.6)	110 (14.9)	

Table 2. Clinical performance of antigen test using anterior nasal samples

1		0	1
	•	PCR (nasopharyngeal samples)	
		Positive	Negative
A 4	Positive	37	0
Antigen test	Negative	14	811
Sensitivity		72.5 (58.3-84.1)	
Specificity Positive predictive value Negative predictive value		100 (99	9.3-100)
		100 (86	5.2-100)
		98.3 (97	7.2-99.1)

Sensitivity, specificity, positive predictive value, and negative predictive value are provided with 95% confidence intervals.





